Những podcast The Lancet Haematology hay nhất (2024)

1
In conversation with... Neema Mayor and Caitlin Farrow 17:55

25d ago17:55

17:55

Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom.Bởi The Lancet

1
Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom 17:53

16d ago17:53

17:53

Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00312-0/fulltext?dgcid=buzzs…

1
Lancet Haematology 10 year anniversary - meet the editors 47:21

3M ago47:21

47:21

In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group. Read our Editorial: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00289-8/fulltex…

1
Lancet Haematology 10 year anniversary - meet the editors 47:21

3M ago47:21

47:21

In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group.Bởi The Lancet

1
Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome 8:08

4M ago8:08

8:08

Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients. Continue this conversation on social! Follow us today at... https://twitter.com/thelan…

1
In conversation with... Matteo Giovanni Della Porta 8:08

4M ago8:08

8:08

Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.Bởi The Lancet

1
Kim Linton on follicular lymphoma 9:48

5M ago9:48

9:48

Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00166-2?dgcid=buzzsprout_tlv_podcast_generic_lanhae Continue this conversation o…

1
In conversation with... Kim Linton 9:48

5M ago9:48

9:48

Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma.Bởi The Lancet

1
Judy Truong on ferritin reference levels and iron deficiency 11:17

5M ago11:17

11:17

Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS235…

1
In conversation with... Judy Truong 11:17

5M ago11:17

11:17

Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine.Bởi The Lancet

1
In conversation with... Johannes Schetelig 14:11

6M ago14:11

14:11

Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.Bởi The Lancet

1
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML 14:11

6M ago14:11

14:11

Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065…

1
Banu Aygun on sickle cell anaemia 11:13

7M ago11:13

11:13

Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us toda…

1
In conversation with... Banu Aygun 11:13

7M ago11:13

11:13

Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.Bởi The Lancet

1
In conversation with... Sabine Braat and Katherine Fielding 18:06

10M ago18:06

18:06

Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.Bởi The Lancet

1
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia 18:06

10M ago18:06

18:06

Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https:…

1
Elisabeth Schorb on the MARTA phase 2 trial 9:23

10M ago9:23

9:23

Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast…

1
In conversation with... Elisabeth Schorb 9:23

10M ago9:23

9:23

Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.Bởi The Lancet

1
In conversation with... Stephan Ehl 13:03

11M ago13:03

13:03

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.Bởi The Lancet

1
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies 13:03

11M ago13:03

13:03

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue this conversation on social! Follow us today at..…

1
In conversation with... Sarah O'Brien 13:50

1y ago13:50

13:50

Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.Bởi The Lancet

1
Dr Sarah O'Brien on the PREVAPIX-ALL trial 13:50

1y ago13:50

13:50

Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma. Read the full article: https://www.thelancet.com/journal…

1
In conversation with... Enrico Lopriore 12:33

1y ago12:33

12:33

Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.Bởi The Lancet

1
Enrico Lopriore on haemolytic disease of the fetus and newborn 12:33

1y ago12:33

12:33

Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on …

1
In conversation with... Meletios Dimopoulos

1y ago

—

Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.Bởi The Lancet

1
Meletios Dimopoulos on relapsed and refractory multiple myeloma 11:00

1y ago11:00

11:00

Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcas…

1
In conversation with... Eric Ohuma 16:27

1+ y ago16:27

16:27

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.Bởi The Lancet

1
Eric Ohuma on haemoglobin concentrations and neonatal outcomes 16:27

1+ y ago16:27

16:27

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continu…

1
In conversation with... Margaret Ragni 13:13

1+ y ago13:13

13:13

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.…

1
Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding 13:13

1+ y ago13:13

13:13

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article: https://www.th…

1
In conversation with... Oreofe Odejide and Thomas Kuczmarski 16:32

1+ y ago16:32

16:32

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.Bởi The Lancet

1
Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma 16:32

1+ y ago16:32

16:32

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_gen…

1
In conversation with... Alok Srivastava 18:41

1+ y ago18:41

18:41

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.Bởi The Lancet

1
Alok Srivastava on fitusiran for patients with haemophilia A and B 18:41

2y ago18:41

18:41

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Read the two trials: Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH) https://www.t…

1
Emmanuela E Ambrose on stroke prevention in children with sickle cell disease 11:31

2y ago11:31

11:31

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania Read the full article: Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE) Continue this conversation on social!…

1
In conversation with... Emmanuela E Ambrose 11:31

2y ago11:31

11:31

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in TanzaniaBởi The Lancet

1
Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes 22:10

2y ago22:10

22:10

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia. Read the full article: Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia Continue this conversation on social! Follow us today at... https://twitter.com/thelancet htt…

1
In conversation with... Sumit Gupta 22:10

2y ago22:10

22:10

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.Bởi The Lancet

1
In conversation with... Xiao-Jun Huang 28:10

2y ago28:10

28:10

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.Bởi The Lancet

1
Xiao-Jun Huang on cellular therapy in China 28:10

2y ago28:10

28:10

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China. Read the Series papers: Cellular therapy in China Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://i…

1
Glenn Pierce on haemophilia care in LMICs 34:55

2+ y ago34:55

34:55

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries. Read the full Review: Achieving access to haemophilia care in low-income and lower-middle-income countries Continue this conversation on social! Follow us today at... http…

1
In conversation with... Glenn Pierce 34:55

2+ y ago34:55

34:55

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.Bởi The Lancet

1
Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders 12:50

2+ y ago12:50

12:50

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both. Read the full article: Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Continue this conversation on social! Follow us today at... https:…

1
In conversation with... Amy DeZern 12:50

2+ y ago12:50

12:50

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.Bởi The Lancet

1
In conversation with... Nicholas Crombie and Gavin Perkins 15:05

3y ago15:05

15:05

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care.Bởi The Lancet

1
Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline 15:05

3y ago15:05

15:05

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://inst…

1
In conversation with... Fredrik Schjesvold 12:24

3y ago12:24

12:24

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.Bởi The Lancet

1
Fredrik Schjesvold on OCEAN phase 3 12:24

3y ago12:24

12:24

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article: Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) Continue this conversatio…

1
Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia 11:59

3y ago11:59

11:59

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext Continu…

1
In conversation with... Jacob D Soumerai and Andrew D Zelenetz 11:59

3y ago11:59

11:59

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.Bởi The Lancet

Podcast đáng để nghe

Podcast The Lancet Haematology

Podcast đáng để nghe

Hướng dẫn sử dụng nhanh